Sonic Hedgehog Signaling Inhibition Provides Opportunities for Targeted Therapy by Sulforaphane in Regulating Pancreatic Cancer Stem Cell Self-Renewal

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Rodova, Mariana ^a   Fu, Junsheng ^a   Watkins, Dara Nall ^a   Srivastava, Rakesh K ^a   Shankar, Sharmila ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYCLIN D1; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN BCL 2; SONIC HEDGEHOG PROTEIN; SULFORAPHANE; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR NANOG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL POPULATION; CELL RENEWAL; CLONOGENESIS; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; PANCREAS CANCER; PLURIPOTENT STEM CELL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; NEOPLASTIC STEM CELLS; PANCREAS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; THIOCYANATES; TRANSCRIPTION FACTORS;

ERINACEIDAE;

EID: 84867018979     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046083     Document Type: Article

References (40)

1. Warshaw AL, Fernandez-del Castillo C, (1992) Pancreatic carcinoma. N Engl J Med 326: 455-465.
2. Magee CJ, Ghaneh P, Neoptolemos JP, (2002) Surgical and medical therapy for pancreatic carcinoma. Best Pract Res Clin Gastroenterol 16: 435-455.
3. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
4. Li J, Wientjes MG, Au JL, (2010) Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 12: 223-232.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
6. Lee CJ, Dosch J, Simeone DM, (2008) Pancreatic cancer stem cells. J Clin Oncol 26: 2806-2812.
7. Lee CJ, Li C, Simeone DM, (2008) Human pancreatic cancer stem cells: implications for how we treat pancreatic cancer. Transl Oncol 1: 14-18.
8. Varjosalo M, Taipale J, (2008) Hedgehog: functions and mechanisms. Genes Dev 22: 2454-2472.
9. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, et al. (2008) A paracrine requirement for hedgehog signalling in cancer. Nature 455: 406-410.
10. Rohatgi R, Milenkovic L, Scott MP, (2007) Patched1 regulates hedgehog signaling at the primary cilium. Science 317: 372-376.
11. Osterlund T, Kogerman P, (2006) Hedgehog signalling: how to get from Smo to Ci and Gli. Trends Cell Biol 16: 176-180.
12. Kinzler KW, Ruppert JM, Bigner SH, Vogelstein B, (1988) The GLI gene is a member of the Kruppel family of zinc finger proteins. Nature 332: 371-374.
13. Dorado J, Lonardo E, Miranda-Lorenzo I, Heeschen C, (2011) Pancreatic cancer stem cells: new insights and perspectives. J Gastroenterol 46: 966-973.
14. Lonardo E, Hermann PC, Heeschen C, (2010) Pancreatic cancer stem cells- update and future perspectives. Mol Oncol 4: 431-442.
15. Jeong WS, Kim IW, Hu R, Kong AN, (2004) Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm Res 21: 661-670.
16. Clarke JD, Dashwood RH, Ho E, (2008) Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 269: 291-304.
17. Gills JJ, Jeffery EH, Matusheski NV, Moon RC, Lantvit DD, et al. (2006) Sulforaphane prevents mouse skin tumorigenesis during the stage of promotion. Cancer Lett 236: 72-79.
18. Hunakova L, Sedlakova O, Cholujova D, Gronesova P, Duraj J, et al. (2009) Modulation of markers associated with aggressive phenotype in MDA-MB-231 breast carcinoma cells by sulforaphane. Neoplasma 56: 548-556.
19. Shankar S, Ganapathy S, Srivastava RK, (2008) Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis and angiogenesis. Clinical Cancer Res 14: 1-16.
20. Roy SK, Srivastava RK, Shankar S, (2010) Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 5: 10.
21. Singh BN, Fu J, Srivastava RK, Shankar S, (2011) Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS ONE 6: e27306.
22. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, et al. (2011) Resveratrol inhibits pancreatic cancer stem cell characteristics in human and kras transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS ONE 6: e16530.
23. Cavaleri F, Scholer HR, (2003) Nanog: a new recruit to the embryonic stem cell orchestra. Cell 113: 551-552.
24. Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, et al. (2009) Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev 18: 1093-1108.
25. Lau J, Kawahira H, Hebrok M, (2006) Hedgehog signaling in pancreas development and disease. Cell Mol Life Sci 63: 642-652.
26. Morton JP, Lewis BC, (2007) Shh signaling and pancreatic cancer: implications for therapy? Cell Cycle 6: 1553-1557.
27. Tanaka H, Nakamura M, Kameda C, Kubo M, Sato N, et al. (2009) The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells. Anticancer Res 29: 2147-2157.
28. Kelleher FC, (2010) Hedgehog signalling and therapeutics in pancreatic cancer. Carcinogenesis.
29. Ward JW, Hu DJ, Alter MJ, Kanwal F, Taylor C, et al. (2010) Transforming strategies for the prevention of chronic HBV and HCV infections. J Fam Pract 59: S23-28.
30. Hanlon N, Coldham N, Gielbert A, Kuhnert N, Sauer MJ, et al. (2008) Absolute bioavailability and dose-dependent pharmacokinetic behaviour of dietary doses of the chemopreventive isothiocyanate sulforaphane in rat. Br J Nutr 99: 559-564.
31. Rushmore TH, Kong AN, (2002) Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 3: 481-490.
32. Chung FL, Conaway CC, Rao CV, Reddy BS, (2000) Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis 21: 2287-2291.
33. Singh AV, Xiao D, Lew KL, Dhir R, Singh SV, (2004) Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis 25: 83-90.
34. Jackson SJ, Singletary KW, (2004) Sulforaphane inhibits human MCF-7 mammary cancer cell mitotic progression and tubulin polymerization. J Nutr 134: 2229-2236.
35. Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, et al. (2011) Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther 19: 188-195.
36. Li Y, Wicha MS, Schwartz SJ, Sun D, (2011) Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem 22: 799-806.
37. Li Y, Kong D, Ahmad A, Bao B, Sarkar FH, (2012) Pancreatic cancer stem cells: Emerging target for designing novel therapy. Cancer Lett.
38. Srivastava RK, Tang SN, Zhu W, Meeker D, Shankar S, (2010) Sulforaphane inhibits self-renewal capacity of pancreatic cancer stem cells and synergizes with quercetin. Front Biosci in press.
39. Tang SN, Singh C, Nall D, Meeker D, Shankar S, et al. (2010) The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal 5: 14.
40. Srivastava RK, Tang SN, Zhu W, Meeker D, Shankar S, (2011) Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells. Front Biosci (Elite Ed) 3: 515-528.